Biospecifics Technologies (BSTC) Reports Q2 EPS of $0.24

Biospecifics Technologies (NASDAQ: BSTC) reported Q2 EPS of $0.24, versus $0.08 reported last year. Revenue for the quarter came in at $4.7 million versus the consensus estimate of $2.6 million.

For earnings history and earnings-related data on Biospecifics Technologies (BSTC) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c